Pure hypercholesterolemia is a clinical diagnosis characterized by the isolated elevation of serum cholesterol, specifically low-density lipoprotein cholesterol (LDL-C), in the absence of significant elevation in triglyceride levels. This condition is a primary driver of atherosclerotic cardiovascular disease (ASCVD) and is categorized into familial (genetic) and polygenic (multifactorial) forms. Familial hypercholesterolemia (FH) results from mutations in the LDLR, APOB, or PCSK9 genes, leading to impaired clearance of LDL from the blood and extremely high lifetime exposure to cholesterol. Polygenic hypercholesterolemia results from a combination of several minor genetic variants and lifestyle factors. Chronic elevation of LDL-C leads to the infiltration of cholesterol into the arterial walls, forming atherosclerotic plaques that can result in myocardial infarction, stroke, or peripheral artery disease. Management involves aggressive LDL-C lowering through lifestyle modifications and pharmacotherapy, including statins, ezetimibe, and PCSK9 inhibitors.
Distinguish between pure hypercholesterolemia and mixed hyperlipidemia.
Example: Patient presents for management of isolated elevated LDL-C of 195 mg/dL with normal triglycerides (90 mg/dL). Clinical diagnosis: Pure hypercholesterolemia. Patient has no history of tobacco use and blood pressure is controlled at 118/75 mmHg. Total ASCVD risk is 7.5 percent. Treatment initiated with Atorvastatin 20mg daily for primary prevention of atherosclerotic cardiovascular disease.
Billing Focus: Documentation must specify the absence of elevated triglycerides to justify the use of E78.0 rather than E78.2 (Mixed hyperlipidemia).
Specify if the condition is familial or non-familial to capture higher specificity codes.
Example: History is notable for a father with an early myocardial infarction at age 42. Genetic testing confirms Heterozygous Familial Hypercholesterolemia. Current LDL is 240 mg/dL despite high-intensity statin. Diagnosis: Pure familial hypercholesterolemia (E78.01). Plan: Referral to cardiology for PCSK9 inhibitor evaluation and screening of first-degree relatives.
Billing Focus: Use E78.01 for familial hypercholesterolemia which carries a higher clinical weight and justifies specialized therapeutics like evolocumab.
Document presence of physical findings such as xanthomas or corneal arcus.
Example: Physical exam reveals bilateral Achilles tendon xanthomas and prominent corneal arcus in a 35-year-old male. Laboratory data shows isolated hypercholesterolemia with LDL 310 mg/dL. Diagnosis: Pure hypercholesterolemia, likely familial. These physical manifestations indicate chronicity and severity of the lipid disorder.
Billing Focus: Physical findings provide clinical evidence supporting the diagnosis, which is critical for medical necessity audits and prior authorizations for non-statin therapies.
Incorporate 10-year ASCVD risk scores into the clinical note.
Example: 52-year-old female with pure hypercholesterolemia. LDL 165 mg/dL. 10-year ASCVD risk calculated at 12.4 percent. Given the moderate risk and pure hypercholesterolemia, patient will start Rosuvastatin 10mg. Patient educated on diet and exercise as adjunctive therapy.
Billing Focus: Providing the risk score justifies the complexity of medical decision making for a 99214 level visit when discussing therapeutic thresholds.
Document statin intolerance or side effects specifically if applicable.
Example: Patient with known pure hypercholesterolemia presents for follow-up. Reports bilateral lower extremity myalgia after three weeks on Simvastatin 40mg. CPK level within normal limits. Discontinuing Simvastatin; diagnosis now includes statin-induced myopathy (G72.0). Will trial Ezetimibe 10mg daily as alternative therapy for E78.0.
Billing Focus: Linking the medication side effect to the primary diagnosis (E78.0) supports the use of higher-cost second-line medications.
Appropriate for stable hypercholesterolemia patients on maintenance therapy with no recent lab changes.
Used when adjusting doses, managing side effects, or coordinating care for high-risk patients (e.g., those with familial hypercholesterolemia).
Standard for a new patient presenting with newly discovered high cholesterol from a screening exam.
The primary diagnostic laboratory test used to confirm and monitor E78.0.
Basic screening test for hypercholesterolemia.
Assists in calculating LDL and assessing total cardiovascular risk.
Crucial for accurately assessing E78.0 when standard calculations are insufficient.
Often performed to screen for silent ischemia in high-cholesterol patients.
Used to differentiate complex cases of Fredrickson's types (IIa vs IIb).
Used for the administration of PCSK9 inhibitors in the office setting.